Urine Omics Predicting IO Therapy Responses in mRCC Patients

This is a multi-center single-arm translational study where patients with mRCC who are to receive pre-determined IO-based therapy will be invited to participate the study. After signing the approved informed consent, eligible and consenting subjects will donate their fresh urine samples for subsequent untargeted metabolomics and proteomics study via GS-MS/MS and/or LC-MS/MS to identify potential metabolite and protein markers that are able to predict efficacy and side effects of IO-based therapies. All subjects in the first-line, maintenance after 1st line, second-line, or subsequent lines of IO-based therapy will be invited and recruited, but those who have received any IO-based therapy before the study can NOT be recruited.

Inclusion criteria

• Age > 20 years
• Subjects diagnosed as advanced or metastatic renal cell carcinoma (a/mRCC)
• Subjects who are about to receive IO-based therapy
• ECOG performance 0, 1, 2, and 3
• Life expectancy >3 months
• eGFR > 15 ml/min/1.73 m2 (Stage IV Chronic Kidney Disease or better)
• Willing to sign the informed consent form

Exclusion criteria

• Subjects NOT willing to sign the informed consent form
• Subjects with active infection or active urinary tract infection, as shown by urinary WBC > 5/HPF
• Subjects having co-existing other malignancies that need active treatment. Those subjects with other malignancies that do not need active treatment are allowed to join the study.
• Subjects taking any immune-modulating agents, including but not limited to corticosteroid, immune-suppressants, etc. at the discretion of recruiting investigators
• Subjects who have taken any IO-based therapy before.
• Subjects who have received other systemic anti-cancer therapies within 4 weeks of screening are not allowed. However, subjects who had a washout period of the above agents for >4 weeks are allowed to enroll. Subjects who have received or are receiving targeted therapy are allowed to join the study.